Another PARP inhibitor showing promise

PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.

The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration

 

Continue reading “Another PARP inhibitor showing promise”

Triple Negative Metastatic Breast Cancer

Triple negative (TNBC) metastatic breast cancer is a heterogeneous disease, chemotherapy remains the mainstay of treatment, however, new treatments based on identifying molecular subtypes, stratifying TNBC based on gene expression assays with subsequent specific targeted therapy is an area of intense clinical research. In this post, I will review our current standard clinical practice and explore ongoing and future clinical directions.

Metastatic TNBC is very heterogenous, and while Basal type is most common, it only account for nearly 80% of all cases.

 

Continue reading “Triple Negative Metastatic Breast Cancer”